Daejeon, South Korea

Weon Kyoo You


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Weon Kyoo You: Innovator in Dual-Targeting Protein Technology

Introduction

Weon Kyoo You is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel protein technologies. His innovative work focuses on dual-targeting proteins that have the potential to advance therapeutic applications.

Latest Patents

Weon Kyoo You holds a patent for a dual-targeting protein that specifically binds to delta-like ligand 4 (DLL4) and vascular endothelial cell growth factor (VEGF). This invention, titled "Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof," represents a significant advancement in targeted therapies. The patent highlights the unique composition of the protein, which includes a specific binding mechanism that could enhance treatment efficacy.

Career Highlights

Currently, Weon Kyoo You is associated with Abl Bio Inc., a company known for its innovative approaches in biopharmaceuticals. His work at Abl Bio Inc. has positioned him as a key player in the development of cutting-edge therapeutic solutions. With a focus on protein engineering, he continues to push the boundaries of what is possible in medical science.

Collaborations

Weon Kyoo You collaborates with notable colleagues, including Dong Heon Lee and Kyung Duk Moon. These partnerships foster a dynamic environment for research and innovation, allowing for the exchange of ideas and expertise that drive advancements in their field.

Conclusion

Weon Kyoo You's contributions to the field of biotechnology, particularly through his patented dual-targeting protein technology, exemplify the impact of innovative thinking in medicine. His work continues to inspire advancements that may lead to improved therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…